These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32934023)

  • 1. ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer.
    Shah N; Kesten N; Font-Tello A; Chang MEK; Vadhi R; Lim K; Flory MR; Cejas P; Mohammed H; Long HW; Brown M
    Cancer Res; 2020 Nov; 80(21):4612-4619. PubMed ID: 32934023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
    Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
    Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
    Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
    Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.
    Li F; Yuan Q; Di W; Xia X; Liu Z; Mao N; Li L; Li C; He J; Li Y; Guo W; Zhang X; Zhu Y; Aji R; Wang S; Tong X; Ji H; Chi P; Carver B; Wang Y; Chen Y; Gao D
    J Clin Invest; 2020 Nov; 130(11):5924-5941. PubMed ID: 32701507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
    Mounir Z; Korn JM; Westerling T; Lin F; Kirby CA; Schirle M; McAllister G; Hoffman G; Ramadan N; Hartung A; Feng Y; Kipp DR; Quinn C; Fodor M; Baird J; Schoumacher M; Meyer R; Deeds J; Buchwalter G; Stams T; Keen N; Sellers WR; Brown M; Pagliarini RA
    Elife; 2016 May; 5():. PubMed ID: 27183006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
    Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
    Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
    Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
    Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
    Mao N; Gao D; Hu W; Hieronymus H; Wang S; Lee YS; Lee C; Choi D; Gopalan A; Chen Y; Carver BS
    Mol Cancer Ther; 2019 Sep; 18(9):1577-1586. PubMed ID: 31296553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
    Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells.
    Zhang Z; Chng KR; Lingadahalli S; Chen Z; Liu MH; Do HH; Cai S; Rinaldi N; Poh HM; Li G; Sung YY; Heng CL; Core LJ; Tan SK; Ruan X; Lis JT; Kellis M; Ruan Y; Sung WK; Cheung E
    Genome Res; 2019 Feb; 29(2):223-235. PubMed ID: 30606742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Mao N; Gao D; Hu W; Gadal S; Hieronymus H; Wang S; Lee YS; Sullivan P; Zhang Z; Choi D; Rosen N; Sawyers CL; Gopalan A; Chen Y; Carver BS
    Cancer Res; 2020 Apr; 80(7):1428-1437. PubMed ID: 32015092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells.
    Strittmatter BG; Jerde TJ; Hollenhorst PC
    PLoS Genet; 2021 Jul; 17(7):e1009708. PubMed ID: 34314419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Significance of ERG and Androgen Receptor Expression in Adenocarcinoma Prostate.
    Husain I; Sagar P; Shukla S; Babu S; Singhai A; Sankhwar SN; Husain N
    Kathmandu Univ Med J (KUMJ); 2018 Oct.-Dec.; 16(64):277-280. PubMed ID: 31729338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
    Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
    Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
    Wasmuth EV; Hoover EA; Antar A; Klinge S; Chen Y; Sawyers CL
    Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8584-8592. PubMed ID: 32220959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.